ziltivekimab
Phase 3- Indications
- Cardiovascular disease, Chronic kidney disease, Inflammation
Company intelligence / Profile preview
Praktyka Lekarska Mateusz Sidor
Krakow, Małopolskie, Polandpmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Serves as a clinical trial site for the ZEUS study investigating ziltivekimab compared to placebo in people with cardiovascular disease, chronic kidney disease, and inflammation[3][8]
- Therapeutic areas
- CardiovascularImmunologyNephrology
- Industry
- Contract Research Organization
02
Drug pipeline
1 asset03
Partnerships
Novo Nordisk (clinical trial sponsor)[3]
Beyond the preview
Go deeper on Praktyka Lekarska Mateusz Sidor.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Praktyka Lekarska Mateusz Sidor.